Gemtuzumab

Base Information

• Chemical Name: Gemtuzumab
• CAS No.: 220578-59-6
• Molecular Weight: 1209.3983
• Mol file: 220578-59-6.mol

Synonyms:ImmunoglobulinG4 (anti-(human CD33 (antigen)) (human-mouse monoclonal hP67.6 g4-chain)),disulfide with human-mouse monoclonal hP67.6 k-chain, dimer,methyl [(1R,4Z,8S,13E)-8-[[2-O-[4-(acetylethylamino)-2,4-dideoxy-3-O-methyl-a-L-threo-pentopyranosyl]-4,6-dideoxy-4-[[[2,6-dideoxy-4-S-[4-[(6-deoxy-3-O-methyl-a-L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl]-4-thio-b-D-ribo-hexopyranosyl]oxy]amino]-b-D-glucopyranosyl]oxy]-13-[2-[[3-[[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazino]-1,1-dimethyl-3-oxopropyl]dithio]ethylidene]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl]carbamateconjugate (9CI); CDP 771; CMA 676; Gemtuzumab; Gemtuzumab ozogamicin;Gemtuzumab zogamicin; Mylotarg; WAY-CMA 676

Chemical Property of Gemtuzumab

Chemical Property:

• PSA: 0.00000
• Density: 1.44g/cm³
• LogP: 0.00000

Purity/Quality:

99% ^*data from raw suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Description: Gemtuzumab ozogamicin was launched as the first antibody-targeted antineoplastic agent for treatment of patients with acute myeloid leukemia (AML). This immunoconjugate consists of an anti-CD33 humanized mouse monoclonat antibody (lgG4) linked via a bifunctional linker to the cytotoxic antibiotic calicheamicin. Once, the anti-CD33 binds to its antigen expressed on AML blast cells, a complex forms that is internalized, eventually releasing the calicheamicin derivative inside the cell. The released antibiotic binds to the minor groove of DNA and after Bergman cyclization induces double-strand breaks and cell-death. Results from both phase I and II clinical trials suggested that this drug, when administered (9 mg/m2 as 2 i.v. infusions separated by 14 days) as a single agent to patients in first relapse, demonstrates an acceptable safety profile, while achieving meaningful clinical remission in 32 to 43% of individuals. Gemtuzumab ozogamicin is considered at least as effective as conventional therapy but presents a more favorable tolerability profile as compared to standard chemo-therapeutic drugs commonly used to treat AML. This agent received accelerated approval from the FDA for the treatment of patients in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy.
• Uses: Treatment of relapsed, acute myelogenous leukemia (cytotoxic calicheamicin derivative conjugated to a humanized monoclonal antibody).